RxDoctor Payments Data

Ashley Davis

Family · Kingsport, TNNPI 1124538780

Payments from drug & device makers

$5,295in general payments, 2019–2025

Across 306 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$824
  • Johnson & Johnson$818
  • UCB, Inc.$515
  • Pfizer$301
  • Lilly USA, LLC$212
  • plus $1K from 15 others

What the payments were for

  • Travel & lodging$2014%
  • Food & beverage$4,99494%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,295 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$23,296
Medicare patients
170
Services billed
332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate57$931,413
IbrancePalbociclib66$900,723
RevlimidLenalidomide23$492,541
ImbruvicaIbrutinib24$366,781
PomalystPomalidomide15$337,555
Lenalidomide20$327,052
BrukinsaZanubrutinib18$221,951
VenclextaVenetoclax30$162,175
Imatinib Mesylate23$37,090
Ondansetron Hcl37$3,065
Anastrozole45$817
Megestrol Acetate18$746
Prochlorperazine Maleate19$632
Hydroxyurea33$527
Letrozole21$426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance$301$900,72366 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$48$337,55515 claims
AbbVieVenclexta$1,579$162,17530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.

Other family in Kingsport

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →